Refractory Nivolumab-Induced Myasthenia Gravis Treated With Abatacept

Am J Ther. 2022 Sep-Oct;29(5):e576-e577. doi: 10.1097/MJT.0000000000001405. Epub 2021 Jul 9.

Authors

Waleed Khokher¹, Sapan Bhuta¹, Nithin Kesireddy¹, Ziad Abuhelwa¹, Mohammed Mhanna¹, Saffa Iftikhar¹, Nicholas Horen¹, Ragheb Assaly²

Affiliations

¹ University of Toledo Internal Medicine, Toledo, OH.
² University of Toledo Pulmonary and Critical Care Medicine, Toledo, OH.

PMID: 34264884
DOI: 10.1097/MJT.0000000000001405

No abstract available

Publication types

Letter

MeSH terms

Abatacept
Antibodies, Monoclonal / adverse effects
Humans
Myasthenia Gravis* / chemically induced
Myasthenia Gravis* / drug therapy
Nivolumab* / adverse effects

Substances

Antibodies, Monoclonal
Nivolumab
Abatacept